Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Feb 15, 2018 and accepted by EDGAR at Feb 14, 2018, 23:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-10-01 to 2017-12-31 | $306.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $1.32bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-10-01 to 2017-12-31 | $134.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $496.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | $125.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2017-01-01 to 2017-12-31 | $123.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-10-01 to 2017-12-31 | $10.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2017-01-01 to 2017-12-31 | −$107.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | $100.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | $263.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | $0.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | $1.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-10-01 to 2017-12-31 | $0.40 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | $1.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-10-01 to 2017-12-31 | 256,804,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 253,225,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | $844.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $99.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-12-31 | $1.67bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $2.65bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $3.55bn | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $807.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $1.50bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $2.03bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-18-000009. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.